Notices. Notice of application
498 words·~2 min read·
/register/2026/03/26/2026-05912A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA-1666] Bulk Manufacturer of Controlled Substances Application: SpecGx LLC AGENCY: Drug Enforcement Administration, Justice. ACTION: Notice of application. SUMMARY: SpecGx LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before May 26, 2026.
Such persons may also file a written request for a hearing on the application on or before May 26, 2026. ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *https://www.regulations.gov* and follow the online instructions at that site for submitting comments.
Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *https://www.regulations.gov.* If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on February 4, 2026, SpecGx, LLC, 3600 North Second Street, Saint Louis, Missouri 63147-3457, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):
Controlled substance Drug code Schedule Gamma Hydroxybutyric Acid 2010 I Tetrahydrocannabinols 7370 I Psilocybin 7437 I Codeine-N-oxide 9053 I Dihydromorphine 9145 I Difenoxin 9168 I Morphine-N-oxide 9307 I Normorphine 9313 I Alphamethadol 9605 I Betamethadol 9609 I Norlevorphanol 9634 I Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) 9821 I Butyryl Fentanyl 9822 I Fentanyl related compounds as defined in 21 CFR 1308.11(h) 9850 I Amphetamine 1100 II Methamphetamine 1105 II Lisdexamfetamine 1205 II Methylphenidate 1724 II Nabilone 7379 II ANPP (4-Anilino-N-phenethyl-4-piperidine) 8333 II Phenylacetone 8501 II Codeine 9050 II Dihydrocodeine 9120 II Oxycodone 9143 II Hydromorphone 9150 II Diphenoxylate 9170 II Ecgonine 9180 II Hydrocodone 9193 II Levorphanol 9220 II Isomethadone 9226 II Meperidine 9230 II Meperidine intermediate-A 9232 II Meperidine intermediate-B 9233 II Meperidine intermediate-C 9234 II Methadone 9250 II Methadone intermediate 9254 II Dextropropoxyphene, bulk (non-dosage forms) 9273 II Morphine 9300 II Oripavine 9330 II Thebaine 9333 II Opium tincture 9630 II Opium, powdered 9639 II Oxymorphone 9652 II Noroxymorphone 9668 II Alfentanil 9737 II Remifentanil 9739 II Sufentanil 9740 II Tapentadol 9780 II Fentanyl 9801 II The company plans to bulk manufacture the listed controlled substances for sale to its customers and for internal use to produce non-controlled substances.
In reference to drug code 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture this drug code as synthetic. No other activities for these drug codes are authorized for this registration. Thomas Prevoznik, Deputy Assistant Administrator. [FR Doc. 2026-05912 Filed 3-25-26; 8:45 am]
Connectionstraces to 2
Traces to 2 documents
Citation graph
cites case law
Cites 2Cited by 0 across 0 sources